Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures.

Abstract: A method and system are disclosed for identifying and/or locating complex patterns in an amino acid sequence stored in a computer file or database. According to an aspect of the present invention, techniques are provided to facilitate queries of protein databases. For protein descriptions received in response to the queries, embodiments of the present invention may scan the received protein descriptions to identify and locate Replikin patterns. A Replikin pattern is defined to be a sequence of 7 to about 50 amino acids that include the following three (3) characteristics, each of which may be recognized by an embodiment of the present invention: (1) the sequence has at least one lysine residue located six to ten amino acid residues from a second lysine residue; (2) the sequence has at least one histidine residue; and (3) at least 6% of the amino acids in the sequence are lysine residues.

Abstract: The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease.

Abstract: Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which are immunogenic epitopes responsible for recognition of antigens by the immune system are provided. These glycoconjugates are useful in prevention of influenza virus binding to cells, treatment of schizophrenia and diagnosing chronic viral disease associated with development of cancer.

Abstract: Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which are immunogenic epitopes responsible for recognition of antigens by the immune system are provided. These glycoconjugates are useful in prevention of influenza virus binding to cells, treatment of schizophrenia and diagnosing chronic viral disease associated with development of cancer.

Abstract: The present invention provides a new class of peptides related to rapid replication and their use in diagnosing, preventing and treating disease.

Abstract: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.

Abstract: Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B which are immunogenic epitopes responsible for recognition of antigens by the immune system are provided. These glycoconjugates are useful in prevention of influenza virus binding to cells, treatment of schizophrenia and diagnosing chronic viral disease associated with development of cancer.

Abstract: The present invention provides methods for identifying a class of peptides referred to as replikins and methods of using replikins to stimulate the immune system of a subject. The method of identifying replikin peptides is based on identifying amino acid sequences comprising 7 to about 50 amino acids that contain (1) at least one lysine residue located six to ten residues from a second lysine residue; (2) at least one histidine residue; and (3) at least 6% lysine residues.

Abstract: Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01-107 are disclosed. Also disclosed are isolated peptides of the Small Pox Virus Surface Antigen S Precursor Protein, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Small Pox Virus Surface Antigen S Precursor Protein.

Abstract: Methods for stimulating the immune system of an individual to produce and release antimalignin antibody are disclosed. The method comprises administering an amount of a composition containing malignin, recognin M, recognin L, or a peptide having the immunological specificity thereof. Also disclosed is a device for removing cancer cells from the body of a subject.

Abstract: Glycoconjugates, therapeutic compositions containing the glycoconjugates and therapeutic methods of using the glycoconjugates are disclosed. In particular, peptide constituents of aglyco 10B, which are immunogenic epitopes responsible for recognition of antigens by the immune system are provided. These glycoconjugates are useful in prevention of influenza virus binding to cells, treatment of schizophrenia and diagnosing chronic viral disease associated with development of cancer.

Abstract: Described herein is the production of two products which are distinct species of human anti-malignin antibody, and the production of a cell line which has the distinguishing characteristic of manufacturing both species of anti-malignin antibody at different times. These anti-malignin products are useful to detect the presence of cancerous or malignant tumor cells. Additionally, these anti-malignin products preferentially attach to cancerous or malignant tumor cells in cell collections in vitro or in vivo and thus can be detected by any visible or other signal emitter attached to said anti-malignin product. This preferential attachment to malignant tumor cells also makes these products useful for metabolic and therapeutic purposes with or without an attached cytotoxic agent.

Abstract: Disclosed herein are a novel group of compounds, termed Recognins, and particularly Recognin M and Recognin L produced, respectively, from artificial mammary and lymphoma cancer cells. The Recognins are useful for diagnostic purposes.

Abstract: This invention is directed to a novel group of compounds, herein termed Recognins. Recognins are made by treating malignant tumor cells or artificial cancer cells and separating the desired products. The Recognins may be used to prepare their Chemoreciprocals, i.e., by contacting the Recognins or the Recognins on a support with body fluids. These Chemoreciprocals are useful for diagnostic and therapeutic purposes, i.e., for diagnosing and treating cancers. The Chemoreciprocals are substances which react with immunochemical-like specificity with a Recognin in vivo or in vitro, e.g., in a quantitative precipitin test, in Ouchterlony double diffusion or in immunofluorescence.

Abstract: A product, Astrocytin, derived from brain cancer cells growing in vivo, and the method of preparing same. Astrocytin may be complexed with an inert carrier, such as bromoacetyl cellulose, and employed in tests for brain tumors. The antibody to Astrocytin is also prepared. A complex of Astrocytin and an inert carrier may be further complexed to anti-Astrocytin.

Abstract: The process for producing polypeptide products which are useful in tests for malignant cells is disclosed. The polypeptide products produced by this process are also disclosed. The process employs the steps of extraction of acidic fractionation and formation of a precipitate in the quantitative precipitin test and the Ouchterlony gel diffusion test. The product is characterized by being soluble in acidic solution, insoluble in basic solution, having a particular spectrophotometric absorption and an amino acid residue composition of high proportions of glutamic and aspartic acids and high ratios of glutamic and aspartic acids to histidine.

Abstract: Described herein is the production of two products which are distinct species of anti-malignin antibody, and the production of three artificially produced species of cell each of which has the distinguishing characteristic of manufacturing either one or both species of anti-malignin antibody. These anti-malignin products are useful to detect the presence of cancerous or malignant tumor cells. These anti-malignin products attach preferentially to cancerous or malignant tumor cells in cell collections in vitro or in vivo and thus can be detected by any attached visible or other signal emitter. This preferential attachment to malignant tumor cells also makes these products useful for metabolic and therapeutic purposes.

Abstract: Described herein is the utilization of anti-Malignin TAG products to detect the presence of cancerous or malignant tumor cells. These TAG products attach preferentially to cancerous or malignant tumor cells in cell collections in vitro or in vivo and thus can be detected by any attached visible or other signal emitter.

Abstract: Malignant brain tumors may be diagnosed by comparing the amounts of certain proteins bound to a product, Malignin, derived from brain tumor cells, complexed to an inert carrier, such as bromacetylcellulose.